RESUMO
OBJECTIVE:To observe therapeutic efficacy and safety of pidotimod combined with ceftriaxone sodium in the treatment of elderly bronchopneumonia.METHODS:A total of 164 elderly patients with bronchopneumonia were randomly divided into observation group (82 cases) and control group (82 cases).Based on routine treatment,control group was given Ceftriaxone sodium for injection 2 g added into 0.9％ Sodium chloride solution 100 mL intravenously,once a day.Observation group was additionally given Pidotimod oral solution 7 mL,twice a day,on the basis of control group.Both group were treated for 2 weeks.Clinical efficacy,defervescence time,cough and wheezing disappearance time,chest radiograph improvement time and average hospitalization time were observed in 2 groups.The serum levels of TNF-αt,IL-6,hs-CRP,IgG,IgA and IgM before and after treatment,the occurrence of ADR were observed.RESULTS:Total response rate of observation group (95.12％) was significantly higher than that of control group (81.71％);and defervescence time,cough and wheezing disappearance time,chest radiograph improvement time and average hospitalization time were significantly shorter than control group,with statistical significance (P＜0.05).After treatment,serum levels of TNF-α,IL-6,hs-CRP and IgM in 2 groups were significantly lower than before treatment,and the observation group was significantly lower than the control group;the levels of IgG and IgA in 2 groups were significantly higher than before treatment,and the observation group was significantly higher than the control group,with statistical significance(P＜0.05).There was no statistical significance in the incidence of ADR between 2 groups (P＞0.05).CONCLUSIONS:Pidotimod combined with ceftriaxone shows significant therapeutic efficacy for elderly bronchopneumonia and improve clinical symptoms without increasing the occurrence of ADR.
RESUMO
Objective:To investigate the efficacy of pidotimod in the treatment of elderly patients with bronchial pneumonia and its effect on immune function. Methods: Totally 85 cases of elderly patients with bronchial pneumonia were randomly divided into two groups:the pidotimod treatment group (43 cases) and the conventional therapy group (42 cases). The conventional therapy group was given moxifloxacin 400 mg·d-1 , ivd, the pidotimod treatment group was additionally with pidotimod oral solutions 800 mg,po,bid, and the treatment course was 10 days. The changes of immune function in the two groups were detected, and the symptoms including fever, cough, asthma, rale and lung spots in X-ray radiation and the symptom duration in the two groups were also compared. Results:After the treatment, the levels of CD4, CD4 / CD8 and NK cells in the two groups were significantly higher than those before the treat-ment, the level of CD8 cells and IgA, IgG, IgM expression levels were significantly lower than those before the treatment (P<0. 05), and the changes in the pidotimod treatment group were much notable than those in the conventional therapy group(P<0. 05). The in-cidence of fever, cough, asthma, rale and lung spots in X-ray radiation in the pidotimod treatment group was lower than that in the con-ventional therapy group(P<0. 01), and the symptom duration was shorter than that in the conventional therapy group(P<0. 01). Conclusion:The mechanisms of pidotimod in the effective treatment of bronchial pneumonia in elderly patients are relative to the im-provement of T cell subsets, NK cells and humoral immunity levels and the enhancement of immunity.
